Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
pioglitazone 1 endocrinologydiseasesdrugs
hyperglycemia 1 endocrinologydiseases
hyperinsulinemia 3 endocrinologydiseases
hypertriglyceridemia 1 endocrinologydiseases
metformin 1 endocrinologydiseasesdrugs
niacin 1 endocrinologydiseasesdrugs
obesity 4 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
metformin 38058 ischaemic events. We have limited evidence to suggest that agents that do not cause hypoglycaemia, such as metformin , pioglitazone, empagliflozin and liraglutide are associated with favourable cardiovascular profile [[141]–[144]].
niacin 41517 synthesisSmall molecule inhibitors of PAI-1 synthesis include synthetic and natural products such as niacin , fibrates and butadiene derivatives (reviewed in [[114]]). However, these compounds are not PAI-1 specific,
pioglitazone 38069 We have limited evidence to suggest that agents that do not cause hypoglycaemia, such as metformin, pioglitazone , empagliflozin and liraglutide are associated with favourable cardiovascular profile [[141]–[144]].
Select Disease Character Offset Disease Term Instance
hyperglycemia 32464 as markers of insulin resistance [[115], [129]–[133]]. Hormonal (hyperinsulinemia) and metabolic ( hyperglycemia and hypertriglyceridemia) derangements, typically found in T2DM patients, seem to have a role in elevated
hyperinsulinemia 32431 with glycaemic parameters as well as markers of insulin resistance [[115], [129]–[133]]. Hormonal ( hyperinsulinemia ) and metabolic (hyperglycemia and hypertriglyceridemia) derangements, typically found in T2DM patients,
hyperinsulinemia 32690 of PAI-1 levels in this population [[130]]. Stegenga et al. demonstrated that in healthy subjects, hyperinsulinemia inhibits fibrinolysis, primarily by enhancing PAI-1 secretion, whilst hyperglycaemia stimulates coagulation
hyperinsulinemia 32888 hyperglycaemia stimulates coagulation [[134]]. This group suggests that in T2DM subjects, the presence of both hyperinsulinemia and hyperglycaemia has a procoagulant effect with the simultaneous inhibition of fibrinolysis.There
hypertriglyceridemia 32482 insulin resistance [[115], [129]–[133]]. Hormonal (hyperinsulinemia) and metabolic (hyperglycemia and hypertriglyceridemia ) derangements, typically found in T2DM patients, seem to have a role in elevated levels of PAI-1 levels
obesity 3310 type 2 diabetes (T2DM), arising mainly due to insulin resistance secondary to increased prevalence of obesity . However, the two conditions can overlap as a significant proportion of individuals with T1DM develop
obesity 33067 simultaneous inhibition of fibrinolysis.There is also an association of elevated PAI-1 levels and abdominal obesity as adipose tissue expresses PAI-1 and represents an important source of plasma PAI-1 in obese subjects
obesity 33242 source of plasma PAI-1 in obese subjects [[131]–[133]]. This explains that the combination of T2DM and obesity contribute to an even greater elevation of PAI-1 than obesity or diabetes alone [[135]].Plasminogen
obesity 33304 explains that the combination of T2DM and obesity contribute to an even greater elevation of PAI-1 than obesity or diabetes alone [[135]].Plasminogen in diabetesThe hyperglycaemic environment in diabetes is responsible

You must be authorized to submit a review.